抗体药物偶联物的出现代表着精准肿瘤治疗时代中的一项新策略。数种上皮肿瘤具有滋养层细胞表面抗原2（TROP-2）的过度表达，这代表了预后不良的预测因子和抗癌治疗的有希望的靶点。在本综述中，我们旨在通过广泛的文献研究和筛选最近会议上的提供的摘要/海报收集有关抗TROP-2 ADCs治疗肺癌的可用临床和临床前数据。抗TROP-2 ADCs是一种针对非小细胞和小细胞肺癌亚型的创新性和即将到来的武器，待多项正在进行的临床试验结果。正确的将该药物组合和放置在肺癌治疗途径中，确定可能的获益预测生物标志物，以及特别毒性（即间质性肺病）的最佳管理和影响是下一个需要回答的问题。

The advent of antibody-drug conjugates (ADCs) represents a renewed strategy in the era of precision oncology. Several epithelial tumors harbor overexpression of the trophoblast cell-surface antigen 2 (TROP-2), which represents a predictor of poor prognosis and a promising target for anticancer therapy.In this review, we aim to collect the available preclinical and clinical data regarding anti-TROP-2 ADCs in lung cancer obtained through extensive literature research and screening of the available abstract/posters presented at recent meetings.Anti-TROP-2 ADCs represent an innovative upcoming weapon against both non-small cell lung cancer and small cell lung cancer subtypes, pending the results of several ongoing trials. The proper combination and placement of this agent throughout the lung cancer treatment pathway, the identification of potentially predictive biomarkers of benefit, as well as the optimal management and impact of peculiar toxicity (i.e. interstitial lung disease) are the next questions to be answered.